Zoetis: A Veterinary Speculation

The price-to-earnings ratio, once a lofty 39 – a figure that hinted at boundless optimism, or perhaps delusion – now sits at a mere 21. The lowest it has dared to venture. It’s as if the company, realizing its inflated reputation, has decided to feign modesty. A clever tactic, though one rarely seen in the corridors of high finance. At this price, one begins to suspect a genuine opportunity. Or, at least, a less ruinous gamble.








